Clinical Trials Logo

Nervous System Neoplasms clinical trials

View clinical trials related to Nervous System Neoplasms.

Filter by:

NCT ID: NCT00631137 Terminated - Clinical trials for Brain and Central Nervous System Tumors

Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma

Start date: January 2008
Phase: N/A
Study type: Interventional

RATIONALE: Testosterone gel may be effective in preventing or lessening muscle weakness caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade glioma. PURPOSE: This randomized clinical trial is studying how well testosterone gel works in preventing weakness caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade glioma.

NCT ID: NCT00629187 Terminated - Neoplasm Metastasis Clinical Trials

Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

CN-306
Start date: April 2004
Phase: Phase 1
Study type: Interventional

The goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors. Past studies showed that the maximum dose of temozolomide was limited by low blood counts. The investigators will use blood stem cells collected from bone marrow to help subjects recover their blood counts, a procedure called autologous stem cell transplant or stem cell rescue. This way, the investigators expect to be able to safely deliver very high doses of temozolomide. This study is only available at Tufts Medical Center.

NCT ID: NCT00623077 Terminated - Sarcoma Clinical Trials

MT2004-30: Tomotherapy for Solid Tumors

Start date: August 2005
Phase: Phase 1
Study type: Interventional

RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation therapy used to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bone marrow radiation therapy followed by an autologous stem cell transplant in treating patients with high-risk or relapsed solid tumors.

NCT ID: NCT00616642 Terminated - Clinical trials for Brain and Central Nervous System Tumors

Rosiglitazone in Treating Patients With Pituitary Tumors

Start date: October 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Rosiglitazone may help pituitary adenoma cells become more like normal cells, and grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly diagnosed or residual or recurrent pituitary adenoma.

NCT ID: NCT00572182 Terminated - Clinical trials for Brain and Central Nervous System Tumors

MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer

Start date: July 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of MK0752 in treating young patients with recurrent or refractory CNS cancer.

NCT ID: NCT00516282 Terminated - Clinical trials for Brain and Central Nervous System Tumors

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

Start date: August 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Temozolomide may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of VNP40101M when given together with temozolomide and to see how well it works in treating patients with progressive or relapsed malignant glioma.

NCT ID: NCT00512798 Terminated - Melanoma Clinical Trials

Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

Start date: June 2003
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temozolomide together with bortezomib may kill more tumor cells. PURPOSE: To determine the best dose of bortezomib and temozolomide and to see how well they work in treating patients with advanced refractory solid tumors or melanoma.

NCT ID: NCT00477503 Terminated - Brain Tumors Clinical Trials

Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA

Start date: May 2007
Phase: Phase 1
Study type: Interventional

- Primary Objective will be to evaluate the use of Ga-67 citrate as an alternative radiopharmaceutical for CSF imaging. - Secondary Objective will be to evaluate the biodistribution, pharmacokinetics and radiation dosimetry of In 111 DTPA and gallium-67 after intrathecal injection during remission of leptomeningeal metastasis (LM) and during LM occurrence, remission and recurrence.

NCT ID: NCT00471653 Terminated - Clinical trials for Brain and Central Nervous System Tumors

Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy

Start date: November 11, 2006
Phase:
Study type: Observational

RATIONALE: Studying samples of blood in the laboratory from patients receiving temozolomide may help doctors learn how temozolomide works in the body. It may also help doctors learn more about how a patient's genes may affect the risk of developing thrombocytopenia. PURPOSE: This clinical trial is studying the pharmacokinetics in patients with newly diagnosed high-grade glioma receiving temozolomide and radiation therapy.

NCT ID: NCT00469937 Terminated - Solid Tumor Clinical Trials

Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases

Start date: February 2006
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as lithium, may protect normal cells from the side effects of radiation therapy. Giving lithium together with radiation therapy may allow a higher dose of radiation therapy to be given so that more tumor cells are killed. PURPOSE: This phase I trial is studying the side effects and best dose of lithium when given together with whole-brain radiation therapy in treating patients with brain metastases from primary cancer outside the brain.